[Previous entry: "Instant PDF Gratification: Booz Allen Hamilton's Customer Relationship Management (CRM) Story"] [Main Index] [Next entry: "Rhabdomyolysis, statins, cholesterol ... have we overdone it."]

03/11/2003 Archived Entry: "Risks and benfits of estrogen plus progestin in healthy postmenopausal women"

SCI-BYTES identifies "Risks and benfits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial," by the Writing Group for the Women's Health Initiative Investigators (J.E. Rossouw, et al.) ---JAMA-Journal of the American Medical Association, 288(3):321-33, 17 July 2002 -- as the current hot paper in medicine, cited "82 times in current journal articles indexed by ISI during November-December 2002. No other non-review paper in medicine published in the last two years attracted as many citations during that two-month period." The analysis states the conclusion as "Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women. All-cause mortality was not affected during the trial. The risk-benefit profile found in this trial is not consistent with the requirements for a viable intervention for primary prevention of chronic diseases, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD." -- Interesting.